Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Characteristics and 2nd- and 3rd-line treatments and outcome of patients with DLBCL mostly not receiving stem cell transplantation – data from the German prospective TLN Registry.

Knauf, W., Mohm, J., Eschenburg, H., Zahn, M.-O., Sandner, R., Sauer, A., Abenhardt, W., 2021.

Oncol Res Treat 2021;44(suppl 4):1–329 p. 191.

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2021
Einsatz von neuen Tests und Therapien bei Patientinnen mit metastasiertem triple-negativem Mammakarzinom in der klinischen Routine – Daten aus der deutschen Registerplattform OPAL

M.-O. Zahn, A. Welt, M. Thill, E. Stickeler, M. Zaiss, A. Nusch, E. Engel, L. Kruggel, M. Jänicke, N. Marschner, A. Wöckel, N. Harbeck, T. Decker, OPAL Registergruppe, 2021.

Oncol Res Treat 2021;44(suppl 4):1–329 p. 246

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
OPAL
2021
Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL

M. Thill, M.-O. Zahn, A. Welt, E. Stickeler, A. Nusch, T. Fietz, J. Rauh, N. Wetzel, L. Kruggel, M. Jänicke, N. Marschner, N. Harbeck, A. Wöckel, T. Decker and OPAL study group 2021

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal:
OPAL
2021
Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients.

Gröschel, A., Passlick, B., Stuschke, M., Christopoulos, P., Reck, M., Grah, C., Growth, A., Hipper, A., Chiabudini, M., Fleitz, A., Jänicke, M., Spring, L., Christoph, D. C., Bernhardt, C., Reiser, M., Zahn, M.-O., Sebastian, M., Griesinger, F., Thomas, M., Eberhardt, W., 2021.

Annals of Oncology, Volume 32, Supplement 5, 2021, Pages S935-S936.
https://doi.org/10.1016/j.annonc.2021.08.1765.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2021
Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP Registry real-world cohort (AIO-TRK-0315).

Griesinger F., Sebastian M., Brückl W., Hummel H.-D., Jaeschke B., Kern J., Wesseler C., Jänicke M., Fleitz A., Zacharias S., Hipper A., Groth A., Weichert W., Dörfel S., Petersen V., Schröder J., Wilke J., Eberhardt W.E.E., Thomas M., 2021.

Annals of Oncology, Volume 32, Supplement 5, 2021, Pages S1015-S1016.
https://doi.org/10.1016/j.annonc.2021.08.1926

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2021
Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria

Bartsch R., Lüftner D., Balic M., Rinnerthaler G., Jackisch C., Müller V., Schmidt M., Harbeck N.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: St. Gallen IBCC / Journal:
ELEANOR
2021
Extendierte Adjuvanz mit Neratinib bei Patientinnen mit HER2+ frühem Mammakarzinom: eine multizentrische, prospektive, nicht-interventionelle Studie (NIS) in Deutschland und Österreich

Bartsch R., Lüftner D., Balic M., Rinnerthaler G., Jackisch C., Müller V., Schmidt M., Harbeck N.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal:
ELEANOR
2021
First line therapy with Lenalidomide and Dexamethasone in transplant-ineligible patients with multiple myeloma: Final results of the observational study FIRST-NIS.

Nückel H., Behlendorf T., Schulz H., Schulze M., Söling U., Bürkle D., Koenigsmann M., Medinger T., Dechow T., Schardt C., Vannier C., Niemeier B., Schmidt B., Rauh J., Potthoff K.

Download

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: EHA / Journal:
FIRST-NIS
2021
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)

Zeuschner P., Hölters S., Stöckle M., Seliger B., Mueller A., Bachmann H. S., Grünwald V., Christoph D.C., Stenzl A., Grimm M.-O., Brüning F., Goebell P. J., Augustin M., Roos F., Harde J., Benz-Rüd I., Staehler M., Junker K.

Abstract

Download

Indikation: Nierenzellkarzinom, Renal Cell Carcinoma / Veranstaltung: - / Journal: Cancers
MARC-2
2021
Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.

Staehler, M., Stöckle, M., Christoph, D. C., Stenzl, A., Potthoff, K., Grimm, M.-O., Klein, D., Harde, J., Brüning, F., Goebell, P. J., Augustin, M., Roos, F., Benz-Rüd, I., Marschner, N., Grünwald, V., 2020

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: / Journal: International Journal of Cancer
MARC-2
2021